Zai Lab

Zai Lab EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Zai Lab (9688.HK) as of Nov 5, 2026 is -19.60 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -3.03 % — a change of 546.18% (lower).

EBIT/Assets

-19.60 %

YoY

546.18%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Zai Lab is 2025 -19.60 % . Operating Income to Assets Ratio (EBIT/Assets) of Zai Lab was 2024 -3.03 % . It decreases by 546.18% lower compared to the previous year.

The Zai Lab EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-46.95 USD
Jan 1, 2019
-57.21 USD
Jan 1, 2020
-23.26 USD
Jan 1, 2021
-43.48 USD
Jan 1, 2022
-33.14 USD
Jan 1, 2023
-4.51 USD
Jan 1, 2024
-3.03 USD
Jan 1, 2025
-19.60 USD
The Zai Lab EBIT/Assets history
YEAREBIT/AssetsYoY
-19.60 %+546.18%
-3.03 %-32.74%
-4.51 %-86.39%
-33.14 %-23.79%
-43.48 %+86.96%
-23.26 %-59.35%
-57.21 %+21.87%
-46.95 %+128.04%
-20.59 %+272.59%
-5.53 %-95.29%
-117.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd. focuses on discovering, developing, and commercializing proprietary therapeutics for unmet medical needs in China, particularly in oncology, autoimmune, and infectious diseases. The company's pipeline includes drug candidates such as Niraparib (ZL-2306), ZL-2103, and ZL-1101, which are in various stages from discovery to late-stage clinical programs. Its products target large patient segments requiring innovative treatments within the Chinese healthcare market. The firm's revenue comes from the commercialization of its proprietary drug candidates, which are developed through internal research and strategic partnerships. Zai Lab Ltd. serves the Chinese biopharmaceutical market, targeting healthcare providers, hospitals, and patients seeking advanced therapies for conditions like cancer and autoimmune disorders. The company leverages its pipeline to generate sales through pharmaceutical distribution channels in China. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

Operating Income to Assets Ratio (EBIT/Assets) of Zai Lab is -19.60 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Zai Lab changed from -3.03 % to -19.60 %, representing a 546.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Zai Lab since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Zai Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zai Lab

All Key Metrics — Zai Lab